SGLT-2 Inhibitors in Heart Failure

Globally, 1 in 5 patients are expected to develop heart failure at some point in their lives. With hospital readmission rates teetering around 50%, care for these patients is often complex and expensive. In recent years, sodium-glucose cotransporter-2 inhibitors (SGLT-2) have become a viable option for managing this patient population. This session seeks to compare and contrast the use of SGLT-2 inhibitors in heart failure with other available treatments, helping the practitioner identify patients who may most benefit from this therapy.